Department of Medical Microbiology, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
Department of Internal Medicine, Division of Hematology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands.
J Hosp Infect. 2022 Aug;126:56-63. doi: 10.1016/j.jhin.2022.03.017. Epub 2022 Apr 26.
The human parainfluenza virus 3 (HPIV-3) outbreak at the haemato-oncology ward of the Maastricht University Medical Centre in the summer of 2016.
To describe an effective strategy to control the largest reported HPIV-3 outbreak at an adult haematology-oncology ward in the Netherlands by implementing infection control measures and molecular epidemiology investigation.
Clinical, patient and diagnostic data were both pro- and retrospectively collected. HPIV-3 real-time polymerase chain reaction (HPIV-3 RT-PCR) was validated using oropharyngeal rinse samples. Screening of all new and admitted patients was implemented to identify asymptomatic infection or prolonged shedding of HPIV-3 allowing cohort isolation.
The HPIV-3 outbreak occurred between 9 July and 28 September 2016 and affected 53 patients. HPIV-3 RT-PCR on oropharyngeal rinse samples demonstrated an up to 10-fold higher sensitivity compared with pharyngeal swabs. Monitoring showed that at first positive PCR, 20 patients (38%) were asymptomatic (of which 11 remained asymptomatic) and the average duration of shedding was 14 days (range 1-58). Asymptomatic patients had lower viral load, shorter period of viral shedding (≤14 days) and were mostly immune-competent oncology patients. The outbreak was under control five weeks after implementation of screening of asymptomatic patients.
Implementation of a sensitive screening method identified both symptomatic and asymptomatic patients which had lower viral loads and allowed early cohort isolation. This is especially important in a ward that combines patients with varying immune status, because both immunocompromised and immune-competent patients are likely to spread the HPIV-3 virus, either through prolonged shedding or through asymptomatic course of disease.
2016 年夏,马斯特里赫特大学医学中心血液肿瘤科发生了人类副流感病毒 3(HPIV-3)爆发。
通过实施感染控制措施和分子流行病学调查,描述一种控制荷兰成人血液肿瘤病房最大规模 HPIV-3 爆发的有效策略。
前瞻性和回顾性收集临床、患者和诊断数据。使用咽漱液样本对 HPIV-3 实时聚合酶链反应(HPIV-3 RT-PCR)进行验证。对所有新入院和入院患者进行筛查,以识别无症状感染或 HPIV-3 持续排出,从而进行队列隔离。
HPIV-3 爆发发生在 2016 年 7 月 9 日至 9 月 28 日之间,影响了 53 名患者。与咽拭子相比,咽漱液样本中的 HPIV-3 RT-PCR 显示出高达 10 倍的敏感性。监测显示,首次 PCR 阳性时,20 名患者(38%)无症状(其中 11 名持续无症状),病毒排出平均持续时间为 14 天(范围为 1-58 天)。无症状患者的病毒载量较低,病毒排出时间较短(≤14 天),且大多为免疫功能正常的肿瘤患者。实施无症状患者筛查五周后,疫情得到控制。
实施敏感的筛查方法可识别出具有较低病毒载量且允许早期队列隔离的有症状和无症状患者。这在一个结合了具有不同免疫状态的患者的病房中尤为重要,因为免疫功能低下和免疫功能正常的患者都可能通过延长病毒排出或无症状疾病过程传播 HPIV-3 病毒。